ArticleInvestigational new drugs2013

RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications.

Antonio Garcia-Gomez et al.PubMed ↗Publisher ↗

No numbers read from the abstract.